Altis Labs, an AI software company for drug development, raised a $25 million Series A, CEO Felix Baldauf-Lenschen tells Axios Pro.
Why it matters: AI has shown more progress finding drug candidates than in proving they work in patients, leaving room for tools that could speed clinical development.
